Last updated 2026-07-20
- Raised $82M Series A led by Delos Capital, May 2024
Total raised
$82.0M
Last: Undisclosed Round 2024-06
Stage
Series A
Founded
2022
Headcount
125
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
Averna Therapeutics (formerly Exsilio Therapeutics) is a biotechnology company developing RNA/lipid nanoparticle (LNP)-based genomic medicines. Their proprietary technology focuses on inserting therapeutic genetic instructions into "safe harbor" sites within the human genome to provide durable and safe treatments for a variety of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's platform utilizes an all-RNA system combined with LNP delivery solutions, enabling programmable, potentially redosable, and titratable gene insertion.
Funding history · 1 round · $82.0M total
2024-05
A Round
$82.0M
★ Delos Capital★ Novartis Venture FundInvusOrbiMedDeep InsightArc VenturesInsight PartnersCRISPR TherapeuticsJPMorgan Chase & CoInnovation Endeavors
Headcount over time
From 40 (2024-03) to 54 (2026-03) · +14 (+35%) · 8 points · source: Finder history + radar grounding
Q&A
- What is Averna Therapeutics' primary focus?
- Averna Therapeutics specializes in genomic medicines, developing treatments for genetic disorders, cancer, and autoimmune conditions by inserting therapeutic genes into safe harbor regions of the DNA.
- When was Averna Therapeutics founded?
- Averna Therapeutics was founded in January 2022.
- Where is Averna Therapeutics headquartered?
- Averna Therapeutics is headquartered in Ness Ziona, Center District, Israel.
- How many employees does Averna Therapeutics have?
- Averna Therapeutics has 51-200 employees.
- What is Averna Therapeutics' total funding to date?
- Averna Therapeutics has raised a total of $82,000,000 USD.
- When did Averna Therapeutics complete its last funding round and who were the lead investors?
- In June 2024, Averna Therapeutics completed a funding round of $82,000,000 USD, with.
- What is Averna Therapeutics' current funding stage?
- Averna Therapeutics is currently in its Series A funding stage.
- What is Averna Therapeutics' primary sector?
- Averna Therapeutics' primary sector is Health Tech & Life Sciences.
Team · 3
Roy Amariglio
Founder · Founder
Tal Zaks
Founder · Co-founder
Erez Levanon
Founder · Founding Team Member
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2C
Tags
pharmaceuticalshealthcare
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | avernatx.com/ |
|---|---|
| linkedin.com/company/103303080 |
Identifiers & details
| Legal name | AVERNA THERAPEUTICS LTD |
|---|---|
| Founded | 2022-1 |
| Employees (exact) | 125 |
Radar intelligence
Patents
| EPO | 3 |
|---|
Web history (Wayback)
| Domain | avernatx.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516545126 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-01-24 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | רמון אילן 2 נס ציונה |